SBH Lab
SBH Lab

Consulting Services

Strategic Consulting for Early-Stage Biotechs

At SBH, we understand the challenges that early-stage biotech companies face, especially during discovery and preclinical development. Our consulting model is built for flexibility, efficiency, and to match your goals, offering deep scientific, regulatory, and practical expertise for each stage of your journey.

Whether you need advice or hands-on help, we work with your team to solve important tasks without stretching your resources. You get expert help where and when it matters most—helping you move faster, stay lean, and avoid costly mistakes.

Over the past 28 years, SBH Sciences has helped more than 350 biotechnology, pharmaceutical, and diagnostic companies worldwide. Our team has built and advanced drug programs across many types of projects. We have been involved not only as consultants, but also as co-founders, executives, board members, and investors—bringing a practical, business-minded approach to every project.

From Ideation to Execution—Step by Step

Drug development is a marathon, not a sprint. Start-ups often can’t sustain full in-house teams at every stage, which is why we break the process into manageable steps and provide modular support tailored to your needs.
We work with you to turn your vision into a clear plan, define key milestones, and bring in the right experts for each stage—from target validation through clinical phase.

The core functionality service

Medicinal Chemistry

From ideation to optimization, we design molecules that matter.

Target Engagement & Validation

Our experts have advanced over 100 NCEs into target engagement and validation-real traction, not just theory

Formulation & Delivery

Drug formulations, advanced drug delivery, tissue engineering, devices, and biomaterials-turning ideas into workable solutions

Medical Strategy for Pre-IND/IND

The new art of medical translation-transforming discovery into the “maximal valuable lead” for your pipeline.

Protocol Development

Preclinical and clinical protocol design that moves your program forward, efficiently and effectively.

Regulatory Solutions

We turn regulation into value milestones-cutting unnecessary tox studies and building rational, cost-effective regulatory strategies that actually make sense.

Grant Submission Mastery

Winning strategies and flawless execution for SBIR, NIH, NSF, CDMRP, and more.

Companion & Targeted Diagnostics

Planning and development for diagnostics that add value and differentiation to your program.

Our Mentors

Dr
Dr. Erkan Baloglu
Medicinal Chemistry & Oncology Drug Development Leadership
Read More
Dr-Tami-Rashal
Dr. Tami Rashal
CMO at SBH
Read More
Dr
Dr. Yosef Landesman
Read More
Dr
Dr. Harry Meade
Scientist & Entrepreneur
Read More
Dr
Dr. Raphael Nir
PHD & Entrepreneur
Read More
Dr
Dr. Gary LWG Robinson
PhD
Read More
Dr. Eyal S
Dr. Eyal S. Ron
Consultant in Drug Delivery Formulation
Read More
Adam Nir
Adam Nir
Chief Diagnostic Officer
Read More

Here comes Header

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Contact Us

Dr. Erkan Baloglu

Medicinal Chemistry & Oncology Drug Development Leadership

Dr. Erkan Baloglu brings over 20 years of hands-on leadership in small molecule drug discovery and early clinical development, with a proven ability to turn first-in-class concepts into clinical-stage therapies. As the inventor and program lead behind multiple oncology assets—Eltanexor, Padnarsertib, and co-inventor of KPT-350 (acquired by Biogen)—his work has contributed directly to five INDs and one FDA-approved drug (Selinexor/XPOVIO®). Dr. Baloglu combines deep scientific insight with strategic execution, having advised over 30 biotech and VC-backed companies globally. His experience spans medicinal chemistry, DMPK, CRO management, and translational strategy

Dr Tami Rashal

CMO at SBH Sciences

Dr. Tami Rashal is a board-certified hemato-oncologist and a driving force in medical and regulatory strategy.

Her expertise is underscored by her direct leadership in three NDA submissions achieving regulatory approvals at Karyopharm Therapeutics Inc.

Dr. Rashal has also spearheaded early-stage development, directing multiple IND submissions and strategically overseeing pre-IND efforts at BiVictriX Therapeutics plc, Karyopharm Therapeutics Inc. (Xpovio®, IL-12 programs), and Sporos BioVentures.

Her ability to craft compelling regulatory plans and design robust clinical protocols is evident throughout her extensive experience in guiding drug development programs.

As CMO at SBH Sciences Inc., she leverages this deep strategic acumen to translate promising research into viable clinical assets.

Dr. Yosef Landesman

Here comes a subtitle

Yosef (Yossi) Landesman is a veteran biotech and pharmaceutical executive with over two decades of experience spanning drug discovery, preclinical development, and regulatory strategy.

He played pivotal scientific roles in the development of FDA-approved therapies XPOVIO® (selinexor) and ONPATTRO® (patisiran).

His therapeutic focus includes oncology, neurology, immunology, and rare diseases, with extensive expertise in RNA-based modalities such as siRNA, tRNA, and RNAi.
Yossi has successfully led translational and DMPK strategies, helping programs move efficiently from discovery to IND submission.
He contributes to clinical trial oversight as a member of multiple Data and Safety Monitoring Boards (DSMBs) for oncology studies.

He brings strategic insight into biomarker development, preclinical pharmacology, and integration of early-stage data into clinical planning.

At SBH Sciences, Yossi consults on scientific direction and translational research.

Dr. Harry Meade

Here comes Subtitle

Dr. Meade is a scientist and entrepreneur, with over 40 years of biotechnology experience spanning preclinical research, drug discovery, and biological production using a disruptive technology.

Dr. Meade earned his Ph.D. in biology from MIT and continued in bacterial genetics and industrial strain improvement. In the mid-80s, he initiated a novel production method of producing recombinant proteins in the milk of transgenic animals.

As the Research Leader of GTC/LFB-USA, a company dedicated to this technology, he championed the scientific development of this production method for contract manufacturing, enabling high-level expression of dozens of proteins.

As part of the team, he helped develop two self-funded programs from preclinical and clinical trials resulting in successful approvals for human use. Dr. Meade holds 22 patents and over authored over 30 publications highlightinh progress in the field.

His work is also featured in his Ted Talk Boston, Medicines from Milk. He is currently the Founder and CSO of IGABIO, LLC.

Dr. Raphael Nir

Heres come a subtitle

Dr. Raphael Nir is a biotechnology expert with more than 30 years of experience in drug development, cell biology, and recombinant protein production.

He has founded or co-founded over 20 companies, including Karyopharm Therapeutics, Galectin Sciences, Alma Bio Therapeutics, SBH Sciences, NeuroDex, and SBH Diagnostics. 

Seven of his companies have active clinical-stage programs. He also established ABI-LAB, a major biotech incubator campus in Natick, Massachusetts, which supports over 80 startups across three buildings and continues to expand.

Dr. Nir holds a PhD in biotechnology, as well as degrees in chemistry, biochemistry, and engineering management. Early in his career, he led cell culture and biologics development at Schering Plough.

In 2025, Dr. Nir was named to the Power 100 list in Massachusetts for his leadership in advancing biotech growth through ABI-LAB and beyond.

At SBH, he guides scientific strategy, operational design, and translational planning—grounded in how drugs are truly designed, developed, and delivered.

Consulting Services

Here comes a subtite

Dr. Gary LWG Robinson is a PhD in Immunology and Biochemistry with over 30 years of experience in early-stage drug development. He is the founder of PhaseDesign Research and co-founder of RFE, Ketogen, and other biotech ventures.

Dr. Robinson specializes in regulatory strategy, preclinical planning, and non-dilutive fundraising. He has helped clients raise over $100M in dilutive and $8.5M in non-dilutive capital. He serves as a grant reviewer for NIH and NSF and sits on several translational funding panels.

His expertise spans regulatory strategy, IND-enabling studies, and smart clinical trial design.
He works across cancer, neurological, retinal, and inflammatory diseases, with experience in small molecules, biologics, and devices.

At SBH, Gary advises on non-dilutive financing strategies and efficient development pathways.
He brings a clear, milestone-driven approach that helps teams reach regulatory and clinical goals faster.

Consulting Services

Here comes subtitle

Dr. Eyal Ron brings decades of experience as a serial entrepreneur in life sciences, having co-founded 12 ventures spanning therapeutics, biomaterials, and medtech. His portfolio includes companies such as Cerebrotec, Gelesis, Combinent Biomedical Systems, and Sensei Biomaterials, among others.

Over the years, Dr. Ron has been involved in five successful company exits through IPOs or acquisitions. He played instrumental roles in the development and approval of seven commercial products—ranging from oral sustained-release drugs like Perfusia® and reformulated Marplan®, to implantable and biodegradable systems such as Plenity®, Gliadel®, InFuse®, and ProLease®. His work has also extended into surgical applications, including FocalSeal®, a pioneering biodegradable sealant, and novel protein/peptide delivery systems.

Beyond his entrepreneurial work, Dr. Ron is deeply committed to mentoring the next generation of life sciences innovators. He currently serves on five boards and supports early-stage teams through programs like MassChallenge, Stanford Biodesign, iCORPS, Northeastern’s Venture Mentoring Network, and EIT Health.

At our company, Dr. Ron serves as a consultant in drug delivery formulation and business strategy, drawing on his broad experience to guide product development and long-term growth.

Consulting Services

Here comes subtitle

Adam Nir has led biomarker analysis for over [XX] programs, including [XX] clinical-stage studies, and has consulted for more than [XX] biotech companies.

He brings over a decade of experience in ELISA development, multiplex platforms, and automated Western technologies.

In 2024 alone, his work supported over [XX] diagnostic and translational research projects.

Adam holds dual B.A. degrees in Biochemistry and Political Science from Brandeis University.

He earned his M.A. in International Relations and a Master of Strategic Studies from Tel Aviv University.

At SBH Sciences, Adam serves as Chief Diagnostic Officer, leading a CLIA- and GLP-certified team that supports clients in de-risking programs, meeting regulatory expectations, and advancing diagnostics in oncology, inflammation, and metabolic disease.